Distinct Phenotypic Differences Associated with Differential Amplification of Receptor Tyrosine Kinase Genes at 4q12 in Glioblastoma

Angiogenesis in Glioblastoma Multiforme: Navigating the Maze

(2012) Amanda G. Linkous et al.   Anti-Cancer Agents in Medicinal Chemistry

Receptor Tyrosine Kinase Genes Amplified in Glioblastoma Exhibit a Mutual Exclusivity in Variable Proportions Reflective of Individual Tumor Heterogeneity

(2012) S. E. Little et al.   CANCER RESEARCH

Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response

(2012) N. J. Szerlip et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Mosaic Amplification of Multiple Receptor Tyrosine Kinase Genes in Glioblastoma

(2011) Matija Snuderl et al.   CANCER CELL

Amplification of the PDGFRA, KIT and KDR genes in glioblastoma: a population-based study

(2011) Sumihito Nobusawa et al.   NEUROPATHOLOGY

Differential Properties of Current Tyrosine Kinase Inhibitors in Gastrointestinal Stromal Tumors

(2011) George D. Demetri   SEMINARS IN ONCOLOGY

Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma

(2010) Houtan Noushmehr et al.   CANCER CELL

Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1

(2010) Roel G.W. Verhaak et al.   CANCER CELL

Clinical implications of KIT and PDGFRA genotyping in GIST

(2010) Javier Martín-Broto et al.   Clinical & Translational Oncology

Platelet-derived growth factor receptor tyrosine kinase inhibitors: a review of the recent patent literature

(2010) Yujia Dai   EXPERT OPINION ON THERAPEUTIC PATENTS

Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas

(2009) Christian Hartmann et al.   ACTA NEUROPATHOLOGICA

Phase II Study of Neoadjuvant Imatinib in Glioblastoma: Evaluation of Clinical and Molecular Effects of the Treatment

(2009) E. Razis et al.   CLINICAL CANCER RESEARCH

Cediranib: profile of a novel anti-angiogenic agent in patients with glioblastoma

(2009) Jörg Dietrich et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Tumour microvessel endothelial cell KIT and stem cell factor expression in human solid tumours

(2009) Harri Sihto et al.   HISTOPATHOLOGY

Intratumoral concentrations of imatinib after oral administration in patients with glioblastoma multiforme

(2009) Matthias Holdhoff et al.   JOURNAL OF NEURO-ONCOLOGY

Antiangiogenic therapies for high-grade glioma

(2009) Andrew D. Norden et al.   Nature Reviews Neurology

IDH1andIDH2Mutations in Gliomas

(2009)   NEW ENGLAND JOURNAL OF MEDICINE

Therapeutic potential of novel selective-spectrum kinase inhibitors in oncology

(2008) Patricia M LoRusso et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

(2008) Roger McLendon et al.   NATURE

An Integrated Genomic Analysis of Human Glioblastoma Multiforme

(2008) D. W. Parsons et al.   SCIENCE

Drug Insight: gastrointestinal stromal tumors (GIST)—the solid tumor model for cancer-specific treatment

(2008) Stefan Sleijfer et al.   Nature clinical practice. Oncology